Clinical evaluation of IDAS II, a new electronic device enabling drug adherence monitoring
- 308 Downloads
The goal of this study was to evaluate clinically the acceptability of the IDAS II (Intelligent Drug Administration System), a new electronic device that enables drug adherence monitoring.
IDAS II was compared to another electronic monitor, the Medication Event Monitoring System (MEMS) in a randomised two-way cross-over study involving 24 hypertensive patients treated with irbesartan. Patients used each device for 2 months. The main parameter of evaluation was the patients’ opinion on both devices. Rates of adherence and blood pressure were also assessed.
Most patients considered both devices to be reliable reminders (IDAS II: 75%;MEMS: 84%, p = ns). Ten patients (42%) preferred the MEMS, while 11 (46%) preferred the IDAS II; three (12%) expressed no preference. Patients found the MEMS device easier to use than the IDAS device (p < 0.001) but appreciated the IDAS blister packs better than the MEMS bulk packaging (p < 0.01). Over the 4-month period, the median “taking adherence” was excellent (99.2%) and comparable with both devices. However, the regularity of drug intake timing was higher with the IDAS II (p < 0.01).
IDAS II, a new electronic device enabling drug adherence monitoring without reconditioning of the drugs appears to be a well-accepted device. Overall, practicability and acceptability of the IDAS II and the MEMS device were similar. Thus, IDAS II could be a useful tool for the management of long-term therapies.
KeywordsAcceptability Clinical assessment Electronic monitoring device Hypertension Patient adherence
Funding: This study was supported by a grant from Bang and Olufsen Medicom a/s, Denmark
Conflict of Interest Statement
The authors do not have any conflict of interest. The paper has been written and data analysed independently of BO Medicom, Denmark. There is no financial conflict of interest behind the fact that the study was sponsored by BO Medicom, Denmark.
- 2.Bertholet N, Favrat B, Fallab-Stubi CL, Brunner HR, Burnier M (2000) Why Objective Monitoring of Compliance is Important in the Management of Hypertension. J Clin Hypertens 2:258–262Google Scholar
- 5.Caro JJ, Speckman JL, Salas M, Raggio G, Jackson JD (1999) Effect of initial drug choice on persistence with antihypertensive therapy: the importance of actual practice data. Can Med Assoc J 160:41–46Google Scholar
- 11.Jones JK, Gorkin L, Lian JF, Staffa JA, Fletcher AP (1995) Discontinuation of and changes in treatment after start of new courses of antihypertensive drugs: a study of a United Kingdom population. Br Med J 311:293–295Google Scholar
- 12.Schneider MP, Despland PA, Buclin T, Burnier M (2003) Evaluation of online telemonitoring of drug adherence: a pilot randomised, controlled study in patients with epilepsy. J Inf Technol Healthcare 1:419–435Google Scholar
- 14.World Health Organization (2003) Adherence to Long Term Therapies:eEvidence for Action. World Health Organization, Geneva, pp 1–194Google Scholar